Search for a doctor

David M. Chascsa, M.D.

  1. Gastroenterologist
  2. Internist
  3. Transplant Hepatologist
Request an Appointment

Publications

  1. Jamal F, Hamad A, Elshaer A, Claassen PL, Viggiano T, Barnhill M, Chascsa DMH, Vargas HE, Aqel BA, Lizaola-Mayo BC. Aspirin Use and Liver-Related Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis. Biomedicines. 2026 May 30; 14 (6)
    View PubMed
  2. Jayasekera CR, de Borba Engster PH, Terwilliger EC, Sinha S, Julie Lankton L, Nguyen MC, Chascsa DMH, Barnhill M, Lizaola-Mayo B, Votruba C, Dickson RC. Preemptive anticraving therapies reduce alcohol relapse after liver transplantation in high-risk individuals. Liver Transpl. 2026 May 08. [Epub ahead of print]
    View PubMed
  3. Aceituno L, Magyar C, Tabrizian P, Marino R, Watt K, Chascsa D, Schnickel G, Banz V, Alconchel F, Martagon C, Moctezuma C, Baker T, Nwaduru C, Krendl FJ, Oberhuber R, Ruiz-Ortega L, Demers C, Bucur R, O'Kane G, Vogel A, Minguez B, Sapisochin G. Safety of Immune Checkpoint Inhibitors Prior to Liver Transplantation in Hepatocellular Carcinoma. Aliment Pharmacol Ther. 2026 May; 63 (10):1369-1379 Epub 2026 Feb 04
    View PubMed
  4. Watt KD, Panda S, Pierluissi V, Abarca R, Rusch D, Tapia AL, Chascsa DMH, Abou-Alfa GK, Azhari H. Safety of immunotherapy after liver transplantation-A multicenter study of a prospective standardized clinical practice protocol. Liver Transpl. 2026 May 1; 32 (5):685-692 Epub 2025 Oct 13
    View PubMed
  5. Elmasry S, Lizaola-Mayo B, Delafield NL, Milam AJ, Dickson RC, Chascsa DMH. Revealing disparities: American Indians are deferred and denied for liver transplant at a higher rate due to psychological reasons. Liver Transpl. 2026 Feb 1; 32 (2):278-282 Epub 2025 Aug 12
    View PubMed
  6. Pirozzi A, Hoyek C, Abidoye O, Okano N, Nguyen MC, Byrne T, Aqel B, Chascsa D, Alzubaidi S, Rimassa L, Bekaii-Saab T, Borad MJ. Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report. J Gastrointest Oncol. 2025 Jun 30; 16 (3):1321-1330 Epub 2025 June 26
    View PubMed
  7. Jayasekera CR, Barnhill M, Chascsa DMH, Croome KP, Carey EJ, Vargas HE. Long-Term Outcomes of Fenofibrate for Treatment of Ischemic Cholangiopathy in Donation After Circulatory Death Liver Transplantation. Clin Transplant. 2025 May; 39(5):e70180.
    View PubMed
  8. Nguyen TD, Lam-Himlin D, Lizaola-Mayo B, Chascsa D. Challenging the dogma: reversal of end-stage liver fibrosis with tirzepatide in mash cirrhosis. Transplantology. 2025; 6(3):25.
  9. Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, Bhoori S, Mazzaferro V, Chascsa DMH, Liu MC, Aby ES, Lake JR, Sogbe M, Sangro B, Abdelrahim M, Esmail A, Schmiderer A, Chouik Y, Rudolph M, Sohal D, Giudicelli H, Allaire M, Akce M, Guadagno J, Tow CY, Massoumi H, De Simone P, Kang E, Gartrell RD, Martinez M, Paz-Fumagalli R, Toskich BB, Tran NH, Solino GA, Poltronieri Pacheco DM, Kalman RS, Agopian VG, Mehta N, Parikh ND, Singal AG, Yang JD. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025 Jan; 82 (1):107-119 Epub 2024 July 10
    View PubMed
  10. Elshaer A, Chascsa DMH, Lizaola-Mayo BC. Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Life (Basel). 2024 Jul 3; 14 (7) Epub 2024 July 03
    View PubMed
  11. Liu MC, Lizaola-Mayo B, Jayasekera CR, Mathur AK, Katariya N, Aqel B, Byrne TJ, Chascsa DMH. Downstaging Hepatocellular Carcinoma with Checkpoint Inhibitor Therapy Improves Access to Curative Liver Transplant. J Gastrointest Cancer. 2024 Jun; 55 (2):969-974 Epub 2024 Mar 14
    View PubMed
  12. Liu MC, Chumbe JT, Chascsa DMH , Lizaola-Mayo B. Current Management of Hepatic Encephalopathy. Curr Hepatology Rep. 2024; 23:73-80.
  13. McCain JD, Dickson RC, Cai J, Zhang N, Pungpapong S, Aqel BA, Chascsa DMH. Hepatitis B reactivation after solid organ transplantation: A single-center experience. Journal of Liver Transplantation. 2024; 15:100227.
  14. Barnhill M, Yaman R, Renszel K, Alzubaidi S, Vargas H, Chascsa D. Not Your Typical Hyperammonemia: Non-hepatic Severe Hyperammonemia in an Adult. ACG Case Rep J. 2023 Dec; 10 (12):e01225 Epub 2023 Dec 13
    View PubMed
  15. Barnhill M, Lizaola-Mayo B, Naidu SG, Shah S, Chascsa DMH. Transjugular intrahepatic portosystemic shunt-induced hemolysis in a non-cirrhotic patient: a case report. J Med Case Rep. 2023 Jun 15; 17 (1):245 Epub 2023 June 15
    View PubMed
  16. Jayasekera CR, Barnhill M, Chascsa DM, Aqel B, Carey EJ, Vargas HE. Fenofibrate Improves Outcomes in Ischemic Cholangiopathy After Liver Transplantation. Gastroenterology 2023 Jun; 164 (7):1321-1323.e2 Epub 2023 Mar 06
    View PubMed
  17. Ashcherkin N, Pisipati S, Athale J, Carey EJ, Chascsa D, Adamski J, Shah S. Solid organ graft-versus-host disease in a recipient of a COVID-19 positive liver graft. J Liver Transpl. 2023 May; 10:100154 Epub 2023 Apr 19
    View PubMed
  18. Aby ES, Moafa G, Latt N, Sultan MT, Cacioppo PA, Kumar S, Chung RT, Bloom PP, Gustafson J, Daidone M, Reinus Z, Debes JD, Sandhu S, Sohal A, Khalid S, Roytman M, Catana AM, Wegermann K, Carr RM, Saiman Y, Kassab I, Chen VL, Rabiee A, Rosenberg C, Nguyen V, Gainey C, Zhou K, Chavin K, Lizaola-Mayo BC, Chascsa DM, Varelas L, Moghe A, Dhanasekaran R. Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study. Hepatol Commun. 2023 Jan 01; 7(1):e8874. Epub 2023 Jan 03.
    View PubMed
  19. Gupta S, Gea-Banacloche J, Me HM, Chascsa DMH, Heilman RL, Budhiraja P, Yaman RN, Vikram HR, Zhang N, Joseph AM, Kodali L. Infections following rejection therapies in kidney and liver transplant recipients. Transpl Infect Dis. 2022 Dec; 24 (6):e13981 Epub 2022 Nov 09
    View PubMed
  20. Katariya NN, Lizaola-Mayo BC, Chascsa DM, Giorgakis E, Aqel BA, Moss AA, Uson Junior PLS, Borad MJ, Mathur AK. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. Cancers (Basel). 2022 Apr 19; 14 (9)
    View PubMed
  21. McCain JD, Chascsa DM. Special Considerations in the Management of HIV and Viral Hepatitis Coinfections in Liver Transplantation. Hepat Med. 2022; 14:27-36. Epub 2022 Apr 29.
    View PubMed
  22. Lizaola-Mayo BC, Dickson RC, Lam-Himlin DM, Chascsa DM. Exogenous copper exposure causing clinical wilson disease in a patient with copper deficiency. BMC Gastroenterol. 2021 Jul 8; 21 (1):278 Epub 2021 July 08
    View PubMed
  23. Kim D, Adeniji N, Latt N, Kumar S, Bloom PP, Aby ES, Perumalswami P, Roytman M, Li M, Vogel AS, Catana AM, Wegermann K, Carr RM, Aloman C, Chen VL, Rabiee A, Sadowski B, Nguyen V, Dunn W, Chavin KD, Zhou K, Lizaola-Mayo B, Moghe A, Debes J, Lee TH, Branch AD, Viveiros K, Chan W, Chascsa DM, Kwo P, Dhanasekaran R. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study. Clin Gastroenterol Hepatol. 2021 Jul; 19(7):1469-1479.e19. Epub 2020 Sep 17.
    View PubMed
  24. McCain JD, Chascsa DM, Lindor KD. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients. Expert Opinion on Orphan Drugs. 2021; 9(2):53-66.
  25. Chascsa DM, Ferre EMN, Hadjiyannis Y, Alao H, Natarajan M, Quinones M, Kleiner DE, Simcox TL, Chitsaz E, Rose SR, Hallgren A, Kampe O, Marko J, Ali RO, Auh S, Koh C, Belkaid Y, Lionakis MS, Heller T. APECED-Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. Hepatology. 2021 Mar; 73 (3):1088-1104
    View PubMed
  26. Chascsa DMH, Lindor KD. Emerging therapies for PBC. J Gastroenterol. 2020 Mar; 55 (3):261-272 Epub 2020 Jan 22
    View PubMed
  27. Aguilar MT, Chascsa DM. Update on Emerging Treatment Options for Primary Biliary Cholangitis. Hepat Med. 2020; 12:69-77 Epub 2020 May 25
    View PubMed
  28. Tang DM, Chascsa DM, Chou JY, Ho N, Auh S, Wank SA, Koh C, Kumar S. Helicobacter pylori infection is strongly associated with metabolic syndrome, and weakly associated with non-alcoholic fatty liver disease, in a US Hispanic population. GastroHep. 2019 Oct; 1(6).
  29. Chascsa DM, Lindor KD. Cancer risk, screening and surveillance in primary sclerosing cholangitis. Minerva Gastroenterol Dietol. 2019 Sep; 65 (3):214-228 Epub 2019 June 19
    View PubMed
  30. Lizaola-Mayo BC, Vargas HE, Chascsa DM. Hepatitis C-Positive Organs for Liver and Kidney Transplantation - Emerging Data and Current Management Strategies. Curr Hepatol Reports. 2019 May 18; 18(2019):228-32.
  31. Chascsa DM, Lai JC, Dunn MA, Montano-Loza AJ, Kappus MR, Dasarathy S, Carey EJ. Patient and Caregiver Attitudes and Practices of Exercise in Candidates Listed for Liver Transplantation. Dig Dis Sci. 2018 Dec; 63 (12):3290-3296 Epub 2018 Sept 03
    View PubMed
  32. DeLeon TT, Salomao MA, Aqel BA, Sonbol MB, Yokoda RT, Ali AH, Moss AA, Mathur AK, Chascsa DM, Rakela J, Bryce AH, Borad MJ. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. J Gastrointest Oncol. 2018 Dec; 9 (6):1054-1062
    View PubMed
  33. Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak A, Nidamanuri S, Rodriguez E, Franco D, Ryland K, Keaveny AP, Huskey JL, Smith M, Reddy KS, Taner CB, Vargas HE, Aqel BA. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. Am J Transplant. 2018 Oct; 18 (10):2559-2565 Epub 2018 June 08
    View PubMed
  34. Chascsa DM, Rakela J. Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease. Curr Hepatology Rep. 2018; 17(3):153-155.
  35. Chascsa DM, Lindor KD. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: Is It Really the Same Disease? Clin Liver Dis. 2018 Aug; 22 (3):589-601
    View PubMed
  36. Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol. 2018 Jun; 113 (6):819-828 Epub 2018 May 11
    View PubMed
  37. Chascsa D, Carey EJ, Lindor KD. Old and new treatments for primary biliary cholangitis. Liver Int. 2017 Apr; 37 (4):490-499
    View PubMed
  38. Ferre EM, Rose SR, Rosenzweig SD, Burbelo PD, Romito KR, Niemela JE, Rosen LB, Break TJ, Gu W, Hunsberger S, Browne SK, Hsu AP, Rampertaap S, Swamydas M, Collar AL, Kong HH, Lee CR, Chascsa D, Simcox T, Pham A, Bondici A, Natarajan M, Monsale J, Kleiner DE, Quezado M, Alevizos I, Moutsopoulos NM, Yockey L, Frein C, Soldatos A, Calvo KR, Adjemian J, Similuk MN, Lang DM, Stone KD, Uzel G, Kopp JB, Bishop RJ, Holland SM, Olivier KN, Fleisher TA, Heller T, Winer KK, Lionakis MS. Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight. 2016 Aug 18; 1: (13).
    View PubMed
  39. Mandell MS, Seres T, Lindenfeld J, Biggins SW, Chascsa D, Ahlgren B, Wachs M, Bambha KM. Risk factors associated with acute heart failure during liver transplant surgery: a case control study. Transplantation. 2015 Apr; 99: (4)873-8.
    View PubMed